ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト：[email protected]AIアクセス：llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HCID 13342作成日：2026年10月27日

ビンブラスチン硫酸塩

ビンブラスチン硫酸塩 · ビンブラスチン硫酸 · ビンブラスチン硫酸塩, 結晶 · 硫酸ビンブラスチン · ビンブラスチン 硫酸塩 · ビンブラスチン硫酸塩 (JP17) · ビンブラスチン・硫酸塩 · エキサール

https://huagongshe.com/ja/chemical/13342

ビンブラスチン硫酸塩 の分子構造式

識別子と物理属性

CAS No.143-67-9
分子式C46H58N4O9
平均分子量811 g/mol
単同位体質量810.42037944 g/mol
SMILESCC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
InChIKeyJXLYSJRDGCGARV-CFWMRBGOSA-N
PubChem CID13342
ChEMBLCHEMBL159
EC No.212-734-0
DTXSIDDTXSID8021430
現地名ビンブラスチン硫酸塩

化学・物理的性質

XLogP3.7
極性表面積154
水素結合供与体数3
水素結合受容体数12
回転可能結合数10
重原子数59
形式電荷0
複雑度1,700
医薬品Pharmaceuticals -> Listed in ZINC15
LogP（分配係数）log Kow = 3.703.72
Color/FormSolvated needles from methanol
溶解度NegligibleODORLESS & HYGROSCOPICWHITE TO SLIGHTLY YELLOW, AMORPHOUS OR CRYSTALLINE POWDERFREELY SOL IN WATER /VINBLASTINE SULFATE/Practically insoluble in water, petroleum ethersoluble in alcohols, acetone, ethyl acetate, chloroformH2O: 10 mg/mL>=1 g/100 mL at 24.5 ºC
Human DrugsBreast FeedingLactationMilk, HumanAntineoplastic AgentsAntimitotic AgentsCytotoxic medicines
Endocrine DisruptorsPotential endocrine disrupting compound
DecompositionWhen heated to decomposition it emits toxic fumes of oxides of nitrogen.
融点211-216 °C267 °C (dec.)(lit.)
Optical RotationCrystallizes as hydrate, mp 284-285 °C. Specific optical rotation = - 28 deg at 26 °C/D ( c = 1.01 in methanol)UV max (Methanol): 212, 262, 282, 292 nm (log epsilon = 4.75, 4.28, 4.22, 4,18). Very slightly soluble in ethanol. Practically insoluble in ether. One part is soluble in 10 parts of water, 50 parts of chloroform /Sulfate/Specific optical rotation: -32 deg at 23 °C/D ( c = 0.88 in methanol)
Stability/Shelf LifeSOLN MAY BE STORED IN REFRIGERATOR FOR PERIODS OF 30 DAYS WITHOUT SIGNIFICANT LOSS OF POTENCY /VINBLASTINE SULFATE/
Dissociation ConstantspKa1 = 5.4pKa2 = 7.4
Other Experimental PropertiesDECOMP AT 244-246 °CCRYSTALS /VINBLASTINE DIHYDROCHLORIDE DIHYDRATE/
比旋光度-21.7 º (c=2, CH3OH 21 ºC)
貯蔵条件2-8°C
外観・状態粉
pKa（酸解離定数）7.4
色白い
pH3.5~5.0 (1g/l, 25℃)
臭い無臭
Merck13,10044
BRN3659812
InChIKeyKDQAABAKXDWYSZ-PNYVAJAMSA-N
CAS データベース143-67-9(CAS DataBase Reference)
EPAの化学物質情報Vinblastine sulfate (143-67-9)

化学的特性

Vinblastine sulfate is a white to off-white crystalline powder that is freely soluble in water, soluble in methane, and slightly soluble in ethanol. Its empiric formula is C46H58N4O9.H2SO4 , and it has a molecular weight of 909.07.

安全性と法規制

FDA 要件The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl vinblastine sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Vinblastine sulfate/
Special ReportsWeisburger EKBioassay Program for Carcinogenic Hazards of Cancer Chemotherapeutic AgentsCancer 40: 1935-49 (1977). Route: ip injectionSpecies: rats and mice.Zhou XJ, Rahmani RPreclinical and Clinical Pharmacology of Vinca Alkaloids. Drugs 44 (Suppl 4): 1-1666-9 (1992). Vinca alkaloids, including vinblastine, vincristine, vindesine and vinorelbine, are widely used antineoplastic drugs, either as single agents or in combination with other drugs. Numerous studies have been conducted in animals and humans, using various in vivo and in vitro models, to investigate the pharmacological behavior of this class of antitumor drug.Smith BDAntitumor Update: Vinca Alkaloids and Epipodophyllotoxins. Hosp Formul22 (Apr): 363-4, 367-8 (1987). A review of the toxicity, dosage and administration and indications of vincristine sulfate (Oncovin), vinblastine sulfate (Velban), vindesine, vinzolidine sulfate, etoposide (VP-16-213Vepesid) and teniposide (VM-26) in the treatment of malignancies is presented.
Shipment Methods and Regulations/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Methods for transporting hazardous drugs to the health-care setting should be consistent with environmental protection and national or local regulations for transporting hazardous substances. When hazardous drugs are being transported to the home-care setting, appropriate containers (eg, lined cardboard boxes) and procedures should be used to prevent breakage and contain leakage. ... The drugs must be securely capped or sealed and properly packaged and protected during transport to reduce further the chance of breakage and spillage in a public area such as a corridor or elevator. /Antineoplastic agents/
Skin, Eye, and Respiratory IrritationsCare must be taken to avoid contact of vinblastine sulfate solutions with the eyes as severe irritation and possibly corneal ulceration can result.... A nurse who sought attention 6 days after squirting vinblastine solution in one eye, having developed by this time photophobia, pain, tearing, and redness of the eye, with vision reduced to 1/10 /is described/. Microcystic edema involved the entire corneal epithelium, and in the following days the epithelium ulcerated and came off in small sheets. Healing from the periphery toward the center began 2 wk after the accident, and in 3.5 wk the eye returned to normal.

用途

用途

紡錘体の形成及び微小管の脱 重合を阻害することにより細胞分裂阻害作用 を示します。

説明

Vinblastine sulfate is the salt of an alkaloid extracted from Vinca rosea Linn., a common flowering herb known as the periwinkle (more properly known as Catharanthus roseus G. Don). Previously, the generic name was vincaleukoblastine, abbreviated VLB. It is a stathmokinetic oncolytic agent. When treated in vitro with this preparation, growing cells are arrested in metaphase. Chemical and physical evidence indicate that vinblastine sulfate is a dimeric alkaloid containing both indole and dihydroindole moieties.

使用

Anticancer agent; microtubule disrupter; Induces apoptosis.Vinblastine sulfate is therapeutically used as an antineoplastic. It is also used in the treatment of Hodgkin disease, choriocarcinoma, acute and chronic leukemias.

一般的な説明

Vinblastine Sulfate is the sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties. Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)

製法・合成法

純化方法

Crystallise the sulfate from MeOH or EtOH and dry it in vacuo over conc H2SO4. The free base crystallises from EtOH or MeOH m 211-216o (+ 2MeOH .1 H2O) and forms a stable etherate from Et2O with m 201-211o, and [] D +42o (CHCl3), and UV max at 214 and 259nm (log  4.73 and 4.21). The dihydrochloride has m 244-246o(dec)(MeOH). It is a monoamine oxidase B inhibitor and induces microtubule aggregation. It is an antineoplastic drug for Hodgkin’s lymphoma. [Neuss et al. J Am Chem Soc 81 4754 1959, Jong-KeunSon et al. J Med Chem 33 1845 1990, Warfield & Bouck Science 186 1219 1974, Beilstein 26 III/IV 3167.]

保管条件Vinblastine sulfate sterile powder, vinblastine sulfate injection, and solutions of the drug are light sensitive and must be protected from light. Vinblastine sulfate sterile powder and injection should be refrigerated at 2-8 °C. Following reconstitution of the sterile powder with bacteriostatic sodium chloride injection which contains phenol or benzyl alcohol as a preservative, solutions of the drug have a pH of 3.5-5 and are stable for 28 days when refrigerated at 2-8 °C.
清掃方法/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Spill kits containing all materials needed to clean up spills of hazardous drugs should be assembled or purchased. These kits should be readily available in all areas where hazardous drugs are routinely handled. If hazardous drugs are being prepared or administered in a nonroutine area (home setting or unusual patient-care area), a spill kit should be obtained by the drug handler. The kit should include two pairs of disposable gloves (one outer pair of utility gloves and one inner latex pair)low-permeability, disposable protective garments (coveralls or gown and shoe covers)safety glasses or splash gogglesrespiratorabsorbent, plastic-backed sheets or spill padsdisposable towelingat least 2 sealable thick plastic hazardous waste disposal bags (prelabeled with an appropriate warning label)a disposable scoop for collecting glass fragmentsand a puncture-resistant container for glass fragments. All individuals who routinely handle hazardous drugs must be trained in proper spill management and cleanup procedures. Spills and breakages must be cleaned up immediately according to the following procedures. If the spill is not located in a confined space, the spill area should be identified and other people should be prevented from approaching and spreading the contamination. Wearing protective apparel from the spill kit, workers should remove any broken glass fragments and place them in the puncture-resistant container. Liquids should be absorbed with a spill padpowder should be removed with damp disposable gauze pads or soft toweling. The hazardous material should be completely removed and the area rinsed with water and then cleaned with detergent. The spill cleanup should proceed progressively from areas of lesser to greater contamination. The detergent should be thoroughly rinsed and removed. All contaminated materials should be placed in the disposal bags provided and sealed and transported to a designated containment receptacle. Spills occurring in the biohazard cabinet should be cleaned up immediatelya spill kit should be used if the volume exceeds 150 ml or the contents of one drug vial or ampule. If there is broken glass, utility gloves should be worn to remove it and place it in the puncture-resistant container located in the biohazard cabinet. The biological safety cabinet, including the drain spillage trough, should be thoroughly cleaned. If the spill is not easily and thoroughly contained, the biological safety cabinet should be decontaminated after cleanup. If the spill contaminates the high efficiency particulate air filter, use of the biological safety cabinet should be suspended until the cabinet has been decontaminated and the high efficiency particulate air filter replaced. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ If hazardous drugs are routinely prepared or administered in carpeted areas, special equipment is necessary to remove the spill. Absorbent powder should be substituted for pads or sheets and left in place on the spill for the time recommended by the manufacturer. The powder should then be picked up with a small vacuum unit reserved for hazardous drug cleanup. The carpet should then be cleaned according to usual procedures. The vacuum bag should be removed and discarded or cleaned, and the exterior of the vacuum cleaner should be washed with detergent and rinsed before being covered and stored. The contaminated powder should be discarded into a sealable plastic bag and segregated with other contaminated waste materials. Alternatively, inexpensive wet or dry vacuum units may be purchased for this express use and used with appropriate cleaners. All such units are contaminated, once used, and must be cleaned, stored, and ultimately discarded /properly/ ... The circumstances and handling of spills should be documented. Health-care personnel exposed during spill management should also complete an incident report or exposure form. /Antineoplastic agents/
処分方法SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices./PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All contaminated disposables should be contained in sealable bags for transfer to larger waste containers. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All bottles must be discarded as contaminated waste after decontamination of the biohazard cabinet. All protective apparel (gown, gloves, goggles, and respirator) should be discarded as contaminated waste. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ The contaminated filters must be removed, bagged in thick plastic and prepared for disposal in a hazardous waste dump site or incinerator licensed by the Environmental Protection Agency (EPA). /Antineoplastic agents/For more Disposal Methods (Complete) data for VINBLASTINE (8 total), please visit the HSDB record page.
Preventive Measures/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Accidental contamination of the health-care environment, resulting in exposure of personnel, patients, visitors, and family members to hazardous substances, is prevented by maintaining the physical integrity and security of packages of hazardous drugs. 1. Access to all areas where hazardous drugs are stored is limited to specified authorized staff. 2. A method should be present for identifying to personnel those drugs that require special precautions (eg, cytotoxics). One way to accomplish this is to apply appropriate warning labels to all hazardous drug containers, shelves, and bins where the drug products are stored. ... 3. A method of identifying, for patients and family members, those drugs that require special precautions in the home should be in place. This may be accomplished in the health-care setting, by providing specific labeling for discharge medications, along with written instructions. 4. Methods for identifying shipping cartons of hazardous drugs should be required from manufacturers and distributors of these drugs. 5. Written procedures for handling damaged packages of hazardous drugs should be maintained. Personnel involved in shipping and receiving hazardous drugs should be trained in these procedures, including the proper use of protective garments and equipment. Damaged shipping cartons of hazardous drugs should be received and opened in an isolated area (eg, in a laboratory fume hood, if available, not in a vertical laminar airflow biological safety cabinet used for preparing sterile products). /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Facilities (eg, shelves, carts, counters, and trays) for storing hazardous drugs are designed to prevent breakage and to limit contamination in the event of leakage. Bins, shelves with barriers at the front, or other design features that reduce the chance of drug containers falling to the floor should be used. Hazardous drugs requiring refrigeration should be stored separately from nonhazardous drugs in individual bins designed to prevent breakage and to contain leakage. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Until the reproductive risks (or lack thereof) associated with handling hazardous drugs within a safety program have been substantiated, staff who are pregnant or breast-feeding should be allowed to avoid contact with these drugs. Policies should be in effect that provide these individuals with alternative tasks or responsibilities if they so desire. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ The pharmacy should provide access to information on toxicity, treatment of acute exposure (if available), chemical inactivators, solubility and stability of hazardous drugs (including investigational agents) used in the workplace. /Antineoplastic agents/For more Preventive Measures (Complete) data for VINBLASTINE (19 total), please visit the HSDB record page.
Personal Protective Equipment (PPE)/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Protective apparel: Disposable closed-front gown or coveralls, disposable utility gloves over disposable latex gloves, NIOSH-approved air-purifying half-mask respirator equipped with a high efficiency filter, and eye protection should be worn. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Class 100 clean-air work stations, both horizontal and vertical airflow (with no containment characteristics), are inappropriate engineering controls for handling hazardous drugs because they provide no personnel protection and permit environmental contamination. Although there are no engineering controls designed specifically for the safe handling of hazardous chemicals as sterile products, Class II contained vertical-flow biological safety cabinets (biohazard cabinets) have been adopted for this use. Biohazard cabinetry is, however, designed for the handling of infectious agents, not hazardous chemicals. ... Based on design, ease of use, and cost considerations, Class II contained-vertical-flow biohazard cabinetry is currently recommended for use in preparing sterile doses of hazardous drugs. Class II cabinetry design and performance specifications are defined in NSF Standard 49. Biological safety cabinets selected for use with hazardous drugs should meet NSF Standard 49 specifications to ensure the maximum protection from these engineering controls. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Workers should wear powder free, disposable surgical latex gloves of good quality when preparing hazardous drugs. Selection criteria for gloves should include thickness (especially at the fingertips where stress is the greatest), fit, length, and tactile sensation. ... The practice of double gloving is supported by research that indicates that many glove materials vary in drug permeability even within lotstherefore, double gloving is recommended. ... In general, surgical latex gloves fit better, have appropriate elasticity for double gloving and maintaining the integrity of the glove-gown interface, and have sufficient tactile sensation (even during double gloving) for stringent aseptic procedures. ... Powdered gloves should be avoided. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Workers who are not protected by the containment environment of a biohazard cabinet should use respiratory protection when handling hazardous drugs. Respiratory protection should be an adjunct to and not a substitute for engineering controls. Surgical masks of all types provide no respiratory protection against powdered or liquid aerosols of hazardous drugs. In situations where workers may be exposed to potential eye contact with hazardous drugs, an appropriate plastic face shield or splash goggles should be worn. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ During compounding of hazardous drugs (eg, crushing, dissolving, and preparing an ointment), workers should wear low permeability gowns and double gloves. Compounding should take place in a protective area such as a disposable glove box. If compounding must be done in the open, an area away from drafts and traffic must be selected, and the worker should use appropriate respiratory protection. /Antineoplastic agents/
相互作用Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily, or in patients with hepatic dysfunction. Concurrent administration of vinblastine sulfate with an inhibitor of this metabolic pathway may cause an earlier onset and/or an increased severity of side effects.The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vinblastine sulfate has been reported to have reduced blood levels of the anticonvulsant and to have increased seizure activity.Potential synergistic interactions between vinblastine and recombinant interferon-beta were assessed using median effect analysis. Calculation of the combination index demonstrated values less than 1 (indicating synergy) over a wide range of drug induced growth inhibition for each of four different renal carcinoma cell lines. The degree of synergy observed could not be predicted from the morphology, doubling time, or relative sensitivity of the renal carcinoma cell lines to vinblastine and recombinant interferon-beta. The optimal ratio of vinblastine to recombinant interferon-beta in the combination appeared to be close to the ratio of the concn of each agent which yielded a 50% inhibition of growth. Although simultaneous presence of vinblastine and recombinant interferon-beta in the culture medium was not required to demonstrate a synergistic effect, the minimum exposure time for recombinant interferon-beta was determined to be 7 days. The uptake but not the egress of tritiated vinblastine into renal carcinoma cell line cells was enhanced after growth for 4 days in 2.25 ng/mL of recombinant interferon-beta. Median effect analysis can be shown to be independent of the mechanism of action of vinblastine and recombinant interferon-beta and gives an indication of potential synergistic interactions over a wide range of drug effects. This method may prove useful in the selection of combinations of IFNs and antitumor drugs for clinical study.A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia. Vinblastine and lopinavir-ritonavir interaction was managed with lopinavir-ritonavir interruption around chemotherapy administration, with complete remission and immunovirological success after six cycles.For more Interactions (Complete) data for VINBLASTINE (6 total), please visit the HSDB record page.
環境中動態TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 2,400(SRC), determined from a log Kow of 3.70(2) and a regression-derived equation(3), indicates that vinblastine is expected to have slight mobility in soil(SRC). The pKa1 and pKa2 of vinblastine are 5.4 and 7.4, respectively(4), indicating that this compound will partially exist in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(5). Volatilization from moist soil is not expected because the base exists as a cation and cations do not volatilize. Vinblastine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of <10-8 mm Hg(SRC), determined from a fragment constant method(6). Biodegradation data were not available(SRC, 2008).AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 2,400(SRC), determined from a log Kow of 3.70(2) and a regression-derived equation(3), indicates that vinblastine is expected to adsorb to suspended solids and sediment(SRC). pKa values of 5.4 and 7.4(4) indicate vinblastine will exist partially in the cation form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process(5). According to a classification scheme(6), an estimated BCF of 140(SRC), from its log Kow(2) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is high(SRC), provided the compound is not metabolized by the organism(SRC). Biodegradation data were not available(SRC, 2008).ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), vinblastine, which has an estimated vapor pressure of <10-8 mm Hg a 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase vinblastine may be removed from the air by wet or dry deposition(SRC). Vinblastine contains chromophores that absorb at wavelengths >290 nm(4) and therefore may be susceptible to direct photolysis by sunlight(SRC).
毒性の概要The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
Ongoing Test StatusThe following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical.[Available from: http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=865-21-4]
Effluent ConcentrationsVinblastine was detected, not quantified in hospital waste water from Ruhr University, Germany (detection limit 0.01 mg/L)(1).
Medical Surveillance/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ There is no method available for routine monitoring of personnel for evidence of hazardous drug exposure. Tests for the presence of mutagens or chromosomal damage are not drug specific and are of value only in controlled studies. Chemical analysis of urine for the presence of hazardous drugs at the sensitivity level needed to detect occupational exposure is limited to a few drugs and is not yet commercially available. /Antineoplastic agents/
Soil Adsorption/MobilityThe Koc of vinblastine is estimated as 2,400(SRC), using a log Kow of 3.70(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that vinblastine is expected to have slight mobility in soil. The pKa1 and pKa2 of vinblastine are 5.4 and 7.4(4), respectively, indicating that this compound will partially exist in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(5).
Natural Pollution SourcesVinblastine is derived from periwinkle, Vinca rosea, Linn(1).
Human Toxicity Excerpts/SIGNS AND SYMPTOMS/ Treatment with vinca alkaloids has resulted ... in both vestibular and auditory damage to the eighth cranial nerve. Manifestations include partial or total deafness which may be temporary or permanent, and difficulties with balance including dizziness, nystagmus, and vertigo./SIGNS AND SYMPTOMS/ Symptoms of overdose will appear when greater-than-recommended doses are given. Any dose of vinblastine sulfate that results in elimination of platelets and neutrophils from blood and marrow and their precursors from marrow should be considered life-threatening. The exact dose that will do this in all patients is unknown./SIGNS AND SYMPTOMS/ Clinical as well as experimental studies ... demonstrated that bone-marrow depression, chiefly manifested by leukopenia, is most important cytotoxic effect on normal cells. ... Neurological manifestations /are characterized by/ ... temporary mental depression, paresthesias, loss of deep-tendon reflexes, and more rarely, headache, convulsions, and psychoses ... ./SIGNS AND SYMPTOMS/ ... Dysfunction of autonomic nervous system, with marked constipation, paralytic ileus, urinary retention, bilateral pain and tenderness of parotid glands associated with dryness of mouth, and sinus tachycardia, has been reported at higher doses. GI disturbances, including nausea, vomiting, anorexia, and diarrhea... Dermatological manifestations are infrequent, but loss of hair, vesicular mucositis of mouth, and dermatitis may occur. Extravasation during injection may lead to cellulitis and phlebitis.For more Human Toxicity Excerpts (Complete) data for VINBLASTINE (15 total), please visit the HSDB record page.
Artificial Pollution SourcesVinblastine's production and use as an antineoplastic drug(1) may result in its release to the environment through various waste streams(SRC).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver InjuryDrug-Induced Liver Injury Severity and Toxicity (DILIst)vinblastineDILI NegativeIntravenousDOI:10.1016/j.drudis.2019.09.022
F8-10
水環境危害等級（WGK）3
RTECS 番号YY8400000
輸送番号（UN）1544
毒性LD50 i.v. in mice: 9.5 mg/kg (Lu, Meistrich)
税関コード29399990
危険文句（R）22-37/38-41-61-36/37/38-63-23/24/25
危険表示Xn,T
安全措置（S）26-36/39-53-45-37/39-36/37/39
危険等級6.1(a)Acute Tox. 4 OralMuta. 2Repr. 2
包装等級II
貯蔵分類11 - Combustible Solids
危険度評価（NFPA 704基準/消防庁データ）人的[青]=2